Erratum to: Comparative lung bioavailability of fluticasone/salmeterol via a breath-actuated spacer and conventional plastic spacers (European Journal of Clinical Pharmacology, (2011), 67, 4, (355-363), 10.1007/s00228-010-0989-9);Comparative lung bioavailability of fluticasone/salmeterol via a breath-actuated spacer and conventional plastic spacers

European Journal of Clinical Pharmacology

Volumn 67, Issue 4, 2011, Pages 355-363

  Nair, Arun ^a   McKinlay, Lorna ^a   Williamson, Peter ^a   Short, Philip ^a   Burns, Patricia ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Asthma; Fluticasone; Lung bioavailability; Salmeterol; Seretide; Spacer

Indexed keywords

CREATININE; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE PLUS SALMETEROL; HYDROCORTISONE; PLACEBO; POTASSIUM; SERETIDE 250; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG WITHDRAWAL; FETUS HEART RATE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE URINE LEVEL; INHALATION SPACER; NORMAL HUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TREMOR;

EID: 79954573452     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-017-2259-6     Document Type: Erratum

References (21)

1. British Guideline on the Management of Asthma 2008 Thorax 63 Suppl 4 iv1 iv121
2. Expert Panel Report 3 (EPR-3) (2007) Guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 120[5 Suppl]:S94-138
3. Wilson AM, Dempsey OJ, Coutie WJR, Sims EJ, Lipworth BJ (1999) Importance of drug-device interaction in determining systemic effects of inhaled corticosteroids. Lancet 353(9170):2128 (Pubitemid 29278488)
4. Martin RJ, Szefler SJ, Chinchilli VM et al (2002) Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 165(10):1377-1383 (Pubitemid 34522940)
5. BJ Lipworth JR Seckl 1997 Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids Thorax 52 5 476 482 9176542 10.1136/thx.52.5.476 1:STN:280:DyaK2szhvFKguw%3D%3D (Pubitemid 27278148)
6. Guhan AR, Cooper S, Osbourne J et al (2000) Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 55(8):650-656 (Pubitemid 30468219)
7. Nair A, Clearie K, Menzies D et al (2009) A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination. Pulm Pharmacol Ther 22(4):305-310
8. SM Harding 1990 The human pharmacology of fluticasone propionate Respir Med 84 Suppl A 25 29 2287792 10.1016/S0954-6111(08)80004-2 (Pubitemid 20376961)
9. Thorsson L, Dahlstrom K, Edsbacker S et al (1997) Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 43(2):155-161 (Pubitemid 27085366)
10. Martin RJ, Szefler SJ, Chinchilli VM, Kraft M et al (2002) Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 165(10):1377-1383 (Pubitemid 34522940)
11. Nair A, Menzies D, Barnes M, Burns P et al (2008) Respirable dose delivery of fluticasone propionate from a small valved holding chamber, a compact breath actuated integrated vortex device and a metered dose inhaler. Br J Clin Pharmacol 66(1):20-26 (Pubitemid 351822151)
12. JA Bennett TW Harrison AE Tattersfield 1999 The contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic effects Eur Respir J 13 2 445 448 10065696 10.1183/09031936.99.13244599 1:STN:280: DyaK1M7mtlGkuw%3D%3D (Pubitemid 29086848)
13. Kempsford R, Handel M, Mehta R, De Silva M, Daley-Yates P (2005) Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects. Respir Med 99[Suppl A]:S11-S19 (Pubitemid 40353085)
14. DJ Clark BJ Lipworth 1996 Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device Thorax 51 10 981 984 8977596 10.1136/thx.51.10.981 1:STN:280:DyaK2s7jt1Wnsg%3D%3D (Pubitemid 26360171)
15. J Anhoj H Bisgaard BJ Lipworth 1999 Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children Br J Clin Pharmacol 47 3 333 336 10215759 10.1046/j.1365-2125.1999.00893.x 1:STN:280:DyaK1M3jtlaqug%3D%3D (Pubitemid 29131350)
16. AM Wilson EJ Sims BJ Lipworth 1999 Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment Clin Endocrinol 50 3 329 335 10.1046/j.1365-2265.1999.00652.x 1:CAS:528:DyaK1MXisFOgs7c%3D (Pubitemid 29166712)
17. Dempsey OJ, Humphreys M, Coutie WJR (1999) Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler. Chest 116(4):935-940 (Pubitemid 29491862)
18. Lee DK, Bates CE, Currie GP et al (2004) Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function. Ann Allergy Asthma Immunol 93(3):253-258 (Pubitemid 39280529)
19. SJ Fowler BJ Lipworth 2001 Pharmacokinetics and systemic beta2-adrenoceptor-mediated responses to inhaled salbutamol Br J Clin Pharmacol 51 4 359 362 11318774 10.1046/j.1365-2125.2001.01362.x 1:CAS:528: DC%2BD3MXjslymsLw%3D (Pubitemid 32391493)
20. JA Bennett AE Tattersfield 1997 Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects Thorax 52 5 458 464 9176539 10.1136/thx.52.5.458 1:STN:280:DyaK2szhvFKgtA%3D%3D (Pubitemid 27278145)
21. A Grove BJ Lipworth 1995 Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients Lancet 346 8969 201 206 7616798 10.1016/S0140-6736(95)91265-7 1:CAS:528:DyaK2MXnt1ynsro%3D